Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
NCT06353321
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
To qualitatively determine the imaging performance of PET-CT imaging subsystem of the RefleXion X1 System Device in patients undergoing standard-of-care (SOC) [68Ga]-PSMA-11 PET-CT using Illuccix on the same day.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- Any age
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- University of Texas Southwestern Medical Center
- Last updated on ClinicalTrials.gov
- January 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- Ut Southwestern Medical Center · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.